Evidence map›Paper›PMID 28213644›Full record

ReviewJournal of endocrinological investigation2017

Circulating microRNAs and diabetes mellitus: a novel tool for disease prediction, diagnosis, and staging?

G Sebastiani, L Nigi, G E Grieco, F Mancarella, G Ventriglia, F Dotta

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Journal of endocrinological investigation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04856683 (PRecisiOn MEdicine to Target Frailty of Endocrine-metabolic Origin), which is not on this map. Cited by 45 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 2 pooled it
4.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04856683 unknown statusnot on this mapstarted 2020, after this paper: background citation

PRecisiOn MEdicine to Target Frailty of Endocrine-metabolic Origin

TypeobservationalSponsorUniversity of Roma La SapienzaRan2020 to 2024Enrolled1,100ConditionsFrailty
3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 2 syntheses or guidelines pooled it, 92 citations in OpenAlex.

  1. Epigenetic Mechanisms in Type 2 Diabetes Retinopathy: A Systematic Review.International journal of molecular sciences · 2021
    Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Non-Coding RNAs: Novel Players in Insulin Resistance and Related Diseases.International journal of molecular sciences · 2021
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

G SebastianiDiabetes Unit, Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy.
L NigiDiabetes Unit, Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy.
G E GriecoDiabetes Unit, Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy.
F MancarellaDiabetes Unit, Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy.
G VentrigliaDiabetes Unit, Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy.
F DottaDiabetes Unit, Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy. francesco.dotta@alice.it.ORCID http://orcid.org/0000-0003-4947-7478
University of Siena · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetes is a complex, multifactorial group of metabolic diseases characterized by chronic hyperglycaemia due to pancreatic beta-cell dysfunction and/or loss. It is characterized by an asymptomatic and highly variable prodromic phase, which renders diabetes mellitus difficult to be predicted with sufficient accuracy. Despite several efforts in the identification and standardization of newly trustable. Biomarkers able to predict and follow-up diabetes and to specifically subtype its different forms, few of them have proven of clinical utility. Recently, a new class of endogenous non-coding small RNAs, namely microRNAs, have been indicated as putative biomarkers, being released by cells and tissues and found in a cell-free circulating form in many biological fluids, including serum and/or plasma. MicroRNAs have been initially identified as promising biomarkers in cancer, and nowadays their application has been extended to other diseases, including diabetes. Although an increasing number of studies focused on the evaluation of circulating microRNAs in diabetes, few reproducibly identified microRNAs as biomarkers for disease prediction or follow-up. Technological problems as well as the need to obtain highly standardized operating procedures and methods are still an issue in such research field. In this review, we comprehensively resume the main and most recent findings on circulating microRNAs, and their possible use as biomarkers to predict and follow-up diabetes and its complications, as well as the methodological challenges to standardize accurate operating procedures for their analysis.

Indexed as

BiomarkersCirculating MicroRNADiabetes MellitusHumansBiomarkersCirculating MicroRNA

Identifiers

PMID28213644
OpenAlexW2588221981

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.